Slower CDK4 and faster CDK2 activation in the cell cycle.

CDK inhibitor CDKs G1 cell cycle phase G1/S transition activation mechanism allosteric drug discovery cancer cyclin-dependent kinases

Journal

Structure (London, England : 1993)
ISSN: 1878-4186
Titre abrégé: Structure
Pays: United States
ID NLM: 101087697

Informations de publication

Date de publication:
23 Apr 2024
Historique:
received: 19 11 2023
revised: 08 02 2024
accepted: 09 04 2024
medline: 5 5 2024
pubmed: 5 5 2024
entrez: 4 5 2024
Statut: aheadofprint

Résumé

Dysregulation of cyclin-dependent kinases (CDKs) impacts cell proliferation, driving cancer. Here, we ask why the cyclin-D/CDK4 complex governs cell cycle progression through the longer G1 phase, whereas cyclin-E/CDK2 regulates the shorter G1/S phase transition. We consider available experimental cellular and structural data including cyclin-E's high-level burst, sustained duration of elevated cyclin-D expression, and explicit solvent molecular dynamics simulations of the inactive monomeric and complexed states, to establish the conformational tendencies along the landscape of the distinct activation scenarios of cyclin-D/CDK4 and cyclin-E/CDK2 in the G1 phase and G1/S transition of the cell cycle, respectively. These lead us to propose slower activation of cyclin-D/CDK4 and rapid activation of cyclin-E/CDK2. We provide the mechanisms through which this occurs, offering innovative CDK4 drug design considerations. Our insightful mechanistic work addresses a compelling cell cycle regulation question and illuminates the distinct activation speeds between the G1 and the G1/S phases, which are crucial for function.

Identifiants

pubmed: 38703777
pii: S0969-2126(24)00138-2
doi: 10.1016/j.str.2024.04.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Wengang Zhang (W)

Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD 21702, USA.

Yonglan Liu (Y)

Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD 21702, USA.

Hyunbum Jang (H)

Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

Ruth Nussinov (R)

Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Electronic address: nussinor@mail.nih.gov.

Classifications MeSH